Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

NCT03076437 is registered in ClinicalTrials.gov with Shenzhen Institute for Innovation and Translational Medicine as lead sponsor.

NCT NCT03076437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03076437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Lead sponsor
Shenzhen Institute for Innovation and Translational Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
January 15, 2016
Completion date
December 31, 2019
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, chronic lymphocytic leukemia, lymphoma